Louisiana MCO Physician Administered (PAD) Drug List

Effective Date: October 1, 2026
(updated 10/2/2026)

The Louisiana Medicaid Managed Care Organization (MCO) list of physician administered drugs (PAD) are drugs covered only under the medical benefit and billed accordingly, and will not process as pharmacy claims. This list is in addition to the Fee-for-Service (FFS) fee schedules.

Brand Name	Generic Name	HCPCS code	Route	Drug Class
ADUHELM	aducanumab-avwa	J0172	IV	Alzheimer's Disease Therapy - Amyloid Directed Monoclonal Antibody
EYLEA	aflibercept	J0178	IO	Ophthalmic - Macular Degeneration, Age-Related, Therapy Agents
EYLEA HD	aflibercept	J0177	IO	Ophthalmic - Macular Degeneration, Age-Related, Therapy Agents
LEMTRADA	alemtuzumab	J0202	IV	Multiple Sclerosis Agent - CD52 Specific Monoclonal Antibody
ZEMAIRA	alpha-1-proteinase inhibitor	J0256	IV	Elastase Inhibitors
ARALAST NP	alpha-1-proteinase inhibitor	J0256	IV	Elastase Inhibitors
PROLASTIN C	alpha-1-proteinase inhibitor	J0256	IV	Elastase Inhibitors
ERAXIS	anidulafungin	J0348	IV	Antifungal - Glucan Synthesis Inhibitor, Echinocandins
LENMELDY	atidarsagene autotemcel	J3391	IV	Gene Therapy Agents - CD34+ Hematopoietic Stem Cells (HSCs)
ZYNTEGLO	betibeglogene autotemcel	J3393	IV	Gene Therapy Agents - CD34+ Hematopoietic Stem Cells (HSCs)
ADCETRIS	brentuximab vedotin	J9042	IV	Antineoplastic - Antibody-Drug Conjugates (ADCs)
CRYSVITA	burosumab-twza	J0584	SQ	Fibroblast Growth Factor 23 (FGF23) Inhibitors, Monoclonal Antibody
ILARIS	canakinumab/PF	J0638	SQ	Anti-inflammatory - Interleukin-1 Beta Blockers
CABLIVI	caplacizumab-yhdp	C9047	IJ	Agents to Treat aTTP- anti von Willebrand Factor (vWF) A1 domain
AMONDYS-45	casimersen	J1426	IV	Duchenne Muscular Dystrophy - Exon Skipping Antisense Oligonucleotide
CANCIDAS	caspofungin acetate	J0637	IV	Antifungal - Glucan Synthesis Inhibitor, Echinocandins

Louisiana MCO Physician Administered (PAD) Drug List

Effective Date: October 1, 2026
(updated 10/2/2026)

Brand Name	Generic Name	HCPCS code	Route	Drug Class
CASPOFUNGIN ACETATE	caspofungin acetate	J0637	IV	Antifungal - Glucan Synthesis Inhibitor, Echinocandins
CISPLATIN	cisplatin	J9060	IV	Antineoplastic - Platinum Complexes
DAPTOMYCIN	daptomycin	J0872	IV	Cyclic Lipopeptide Antibiotics
DAPTOMYCIN	daptomycin	J0873	IV	Cyclic Lipopeptide Antibiotics
DAPTOMYCIN	daptomycin	J0877	IV	Cyclic Lipopeptide Antibiotics
DAPTOMYCIN	daptomycin	J0878	IV	Cyclic Lipopeptide Antibiotics
DAPTOMYCIN-0.9% NACL	daptomycin in 0.9 % sodium chloride	J0874	IV	Cyclic Lipopeptide Antibiotics
DARZALEX	daratumumab	J9145	IV	Antineoplastic - CD38 Specific Recombinant Monoclonal Antibody Agents
DAUNORUBICIN HCL	daunorubicin HCl	J9150	IV	Antineoplastic Antibiotic - Anthracyclines
ELEVIDYS	delandistrogene moxeparvovec-rokl	J1413	IV	Duchenne Muscular Dystrophy - Gene Therapy Agents
XGEVA	denosumab	J0897	SQ	RANK ligand (RANKL) inhibitor, MC Antibody
JEMPERLI	dostarlimab-gxly	J9272	IV	Antineoplastic-Anti-Programmed Cell Death Receptor-1 (PD-1) MC Antib.
DOXORUBICIN HCL	doxorubicin HCl	J9000	IV	Antineoplastic Antibiotic - Anthracyclines
ADRIAMYCIN	doxorubicin HCl	J9000	IV	Antineoplastic Antibiotic - Anthracyclines
DOXIL	doxorubicin HCl pegylated liposomal	Q2050	IV	Antineoplastic Antibiotic - Anthracyclines
DOXORUBICIN HCL LIPOSOME	doxorubicin HCl pegylated liposomal	Q2050	IV	Antineoplastic Antibiotic - Anthracyclines
IMFINZI	durvalumab	J9173	IV	Antineoplastic-Anti-Programmed Cell Death Ligand-1 (PD-L1) MC Antib.
SOLIRIS	eculizumab	J1299	IV	Agents to Treat Paroxysmal Nocturnal Hemoglobinuria (PNH)
VYVGART	efgartigimod alfa-fcab	J9332	IV	Antimyasthenic Agent - Neonatal Fc Receptor (FcRn) Inhibitor

Louisiana MCO Physician Administered (PAD) Drug List

Effective Date: October 1, 2026
(updated 10/2/2026)

Brand Name	Generic Name	HCPCS code	Route	Drug Class
VYVGART HYTRULO	efgartigimod alfa-hyaluronidase-qvfc	J9334	SQ	Antimyasthenic Agent - Neonatal Fc Receptor (FcRn) Inhibitor
SKYSONA	elivaldogene autotemcel	J3387	IV	Gene Therapy Agents - CD34+ Hematopoietic Stem Cells (HSCs)
PADCEV	enfortumab vedotin-ejfv	J9177	IV	Antineoplastic - Antibody-Drug Conjugates (ADCs)
HEMGENIX	etranacogene dezaparvovec-drlb	J1411	IV	Gene Therapy Agents - Factor IX Deficiency
CASGEVY	exagamglogene autotemcel	J3392	IV	Sickle Cell Anemia Agents - Cell/Gene Therapy
ENHERTU	fam-trastuzumab deruxtecan-nxki	J9358	IV	Antineoplastic - Antibody-Drug Conjugates (ADCs)
KCENTRA	human prothrombin complex concentrate (PCC), 4-factor	J7168	IV	Factor IX Complex (Prothrombin Complex Concentrate) Preparations
ABECMA	idecabtagene vicleucel	Q2055	IV	Antineoplastic - BCMA directed CAR-T cell immunotherapy
UPLIZNA	inebilizumab-cdon	J1823	IV	Immunosuppressive - CD19 (B Lymphocyte) Monoclonal Antibody
ALDURAZYME	laronidase	J1931	IV	Metabolic Disease Enzyme Replacement, Mucopolysaccharidosis
LYFGENIA	lovotibeglogene autotemcel	J3394	IV	Sickle Cell Anemia Agents - Cell/Gene Therapy
ZEPZELCA	lurbinectedin	J9223	IV	Antineoplastic-Alkylating Agent-Tetrahydroisoquinoline and Derivatives
MICAFUNGIN	micafungin sodium	J2248	IV	Antifungal - Glucan Synthesis Inhibitor, Echinocandins
MICAFUNGIN	micafungin sodium	J2246 (Baxter)	IV	Antifungal - Glucan Synthesis Inhibitor, Echinocandins
MICAFUNGIN	micafungin sodium	J2247 (Par pharm)	IV	Antifungal - Glucan Synthesis Inhibitor, Echinocandins
MYCAMINE	micafungin sodium	J2248	IV	Antifungal - Glucan Synthesis Inhibitor, Echinocandins
DANYELZA	naxitamab-gqgk	J9348	IV	Antineoplastic - Anti-GD2 Ganglioside Monoclonal Antibody
OCREVUS	ocrelizumab	J2350	IV	Multiple Sclerosis Agent - CD20 Specific Monoclonal Antibody

Louisiana MCO Physician Administered (PAD) Drug List

Effective Date: October 1, 2026
(updated 10/2/2026)

Brand Name	Generic Name	HCPCS code	Route	Drug Class
OCREVUS ZUNOVO	ocrelizumab/ hyaluronidase-ocsq	J2351	SQ	Multiple Sclerosis Agent - CD20 Specific Monoclonal Antibody
ARZERRA	ofatumumab	J9302	IV	Antineoplastic - CD20 Specific Recombinant Monoclonal Antibody Agents
ZOLGENSMA	onasemnogene abeparvovec-xioi	J3399	IV	Gene Therapy Agents - SMN Protein Deficiency
PACLITAXEL PROTEIN-BOUND	paclitaxel protein-bound	J9264	IV	Antineoplastic - Taxanes
ABRAXANE	paclitaxel protein-bound	J9264	IV	Antineoplastic - Taxanes
KRYSTEXXA	pegloticase	J2507	IV	Hyperuricemia Therapy - Urate-Oxidase Enzyme-Type
KEYTRUDA	pembrolizumab	J9271	IV	Antineoplastic-Anti-Programmed Cell Death Receptor-1 (PD-1) MC Antib.
ALIMTA	pemetrexed disodium	J9305	IV	Antineoplastic - Antimetabolite - Folic Acid Analogs
AXTLE	pemetrexed dipotassium	J9292	IV	Antineoplastic - Antimetabolite - Folic Acid Analogs
PEMETREXED DISODIUM	pemetrexed disodium	J9305	IV	Antineoplastic - Antimetabolite - Folic Acid Analogs
PEMETREXED DISODIUM	pemetrexed disodium	J9294 (Hospira)	IV	Antineoplastic - Antimetabolite - Folic Acid Analogs
PEMETREXED DISODIUM	pemetrexed disodium	J9297 (Sandoz)	IV	Antineoplastic - Antimetabolite - Folic Acid Analogs
PEMRYDI RTU	pemetrexed disodium	J9324	IV	Antineoplastic - Antimetabolite - Folic Acid Analogs
ULTOMIRIS	ravulizumab-cwvz	J1303	IV	Agents to Treat Paroxysmal Nocturnal Hemoglobinuria (PNH)
RITUXAN	rituximab	J9312	IV	Antineoplastic - CD20 Specific Recombinant Monoclonal Antibody Agents
RITUXAN HYCELA	rituximab/hyaluronidase, human recombinant	J9311	SQ	Antineoplastic - CD20 Specific Recombinant Monoclonal Antibody Agents
TALVEY	talquetamab-tgvs	J3055	SQ	Bispecific GPRC5D-Directed CD3 T-cell Engager, Monoclonal Antibody
TEPEZZA	teprotumumab-trbw	J3241	IV	Thyroid Eye Disease Agents

Louisiana MCO Physician Administered (PAD) Drug List

Effective Date: October 1, 2026
(updated 10/2/2026)

Brand Name	Generic Name	HCPCS code	Route	Drug Class
KYMRIAH	tisagenlecleucel	Q2042	IV	Antineoplastic - CD-19 directed CAR-T cell immunotherapy
HERCEPTIN	trastuzumab	J9355	IV	Epidermal Growth Factor Recept Blocker (HER-2 Type), Rec-MC Antibody
AVTOZMA	tocilizumab-anoh	Q5156	IV	Antirheumatic - Interleukin-6 Receptor Antagonist, Monoclonal Antibody
ROCTAVIAN	valoctocogene roxaparvovec-rvox	J1412	IV	Gene Therapy Agents - Factor VIII Deficiency
VILTEPSO	viltolarsen	J1427	IV	Duchenne Muscular Dystrophy - Exon Skipping Antisense Oligonucleotide
ADENOSINE	adenosine	J0153	IV	Antiarrhythmic Others
KADCYLA	ado-trastuzumab emtansine	J9354	IV	Antineoplastic - Antibody-Drug Conjugates (ADCs)
TECELRA	afamitresgene autoleucel	Q2057	IV	Antineoplastic - MAGE-A4 directed TCR-T cell immunotherapy
FABRAZYME	agalsidase beta	J0180	IV	Metabolic Disease Enzyme Replacement, Fabry's Disease
LUMIZYME	alglucosidase alfa	J0221	IV	Metabolic Disease Enzyme Replacement, Pompe Disease
AMIKACIN SULFATE	amikacin sulfate	J0278	IJ	Aminoglycoside Antibiotic
AMPICILLIN SODIUM	ampicillin sodium	J0290	IJ	Aminopenicillin Antibiotic
THYMOGLOBULIN	anti-thymocyte globulin, rabbit	J7511	IV	Immune Serums
CROFAB	antivenin, crotalidae Fab(ovin)	J0840	IJ	Antivenoms - Snake Antivenoms
TRISENOX	arsenic trioxide	J9017	IV	Antineoplastic - Arsenic Compounds
RYLAZE	asparaginase Erwinia chrysanthemi (recombinant)-rywn	J9021	IM	Antineoplastic - Asparaginase Enzyme Therapy Agents
TECENTRIQ	atezolizumab	J9022	IV	Antineoplastic-Anti-Programmed Cell Death Ligand-1 (PD-L1) MC Antib.
ATROPEN	atropine sulfate	J0461	IM	Muscarinic Receptor Antagonists (Anticholinergic)

Louisiana MCO Physician Administered (PAD) Drug List

Effective Date: October 1, 2026
(updated 10/2/2026)

Brand Name	Generic Name	HCPCS code	Route	Drug Class
ATROPEN	atropine sulfate	J0462	IM	Muscarinic Receptor Antagonists (Anticholinergic)
NEXVIAZYME	avalglucosidase alfa-ngpt	J0219	IV	Metabolic Disease Enzyme Replacement, Pompe Disease
BAVENCIO	avelumab	J9023	IV	Antineoplastic-Anti-Programmed Cell Death Ligand-1 (PD-L1) MC Antib.
YESCARTA	axicabtagene ciloleucel	Q2041	IV	Antineoplastic - CD-19 directed CAR-T cell immunotherapy
VIDAZA	azacitidine	J9025	IJ	Antineoplastic - Antimetabolite - Pyrimidine Analogs
GABLOFEN	baclofen	J0475	IT	Skeletal Muscle Relaxant - Central Muscle Relaxants
GABLOFEN	baclofen	J0476	IT	Skeletal Muscle Relaxant - Central Muscle Relaxants
BCG VACCINE (TICE STRAIN)	BCG vaccine, live/PF	J9030	IJ	Vaccine Bacterial - Other
BLENREP	belantamab mafodotin-blmf	J9053	IV	Antineoplastic - Antibody-Drug Conjugates (ADCs)
BELEODAQ	belinostat	J9032	IV	Antineoplastic - Histone deacetylase (HDAC) inhibitors
TREANDA	bendamustine HCl	J9033	IV	Antineoplastic - Alkylating Agent - Other
BENDEKA	bendamustine HCl	J9034	IV	Antineoplastic - Alkylating Agent - Other
VYJUVEK	beremagene geperpavec-svdt	J3401	TP	Dermatological - Gene Therapy Agents
AVASTIN	bevacizumab	J9035	IV	ANP - Human Vascular Endothelial Growth Factor Inhib Rec-MC Antibody
VEGZELMA	bevacizumab-adcd	Q5129	IV	ANP - Human Vascular Endothelial Growth Factor Inhib Rec-MC Antibody
MVASI	bevacizumab-awwb	Q5107	IV	ANP - Human Vascular Endothelial Growth Factor Inhib Rec-MC Antibody
ZIRABEV	bevacizumab-bvzr	Q5118	IV	ANP - Human Vascular Endothelial Growth Factor Inhib Rec-MC Antibody
ALYMSYS	bevacizumab-maly	Q5126	IV	ANP - Human Vascular Endothelial Growth Factor Inhib Rec-MC Antibody

Louisiana MCO Physician Administered (PAD) Drug List

Effective Date: October 1, 2026
(updated 10/2/2026)

Brand Name	Generic Name	HCPCS code	Route	Drug Class
BLEOMYCIN SULFATE	bleomycin sulfate	J9040	IJ	Antineoplastic Antibiotic - Others
BLINCYTO	blinatumomab	J9039	IV	Bispecific CD19-Directed CD3 T-cell Engager, Monoclonal Antibody
VELCADE	bortezomib	J9041	IJ	Antineoplastic - Proteasome Enzyme Inhibitors
TECARTUS	brexucabtagene autoleucel	Q2053	IV	Antineoplastic - CD-19 directed CAR-T cell immunotherapy
BEOVU	brolucizumab-dbll	J0179	IO	Ophthalmic - Macular Degeneration, Age-Related, Therapy Agents
BUSULFEX	busulfan	J0594	IV	Antineoplastic - Alkylating Agent - Alkyl Sulfonates
JEVTANA	cabazitaxel	J9043	IV	Antineoplastic - Taxanes
ASPARLAS	calaspargase pegol-mknl	J9118	IV	Antineoplastic - Asparaginase Enzyme Therapy Agents
CALCITRIOL	calcitriol	J0636	IV	Vitamins - D Derivatives
CALCIUM GLUCONATE	calcium gluconate	J0612 (Fresenius Kabi)	IV	Minerals and Electrolytes - Calcium Replacement
CALCIUM GLUCONATE	calcium gluconate	J0613 (WG Critical Care)	IV	Minerals and Electrolytes - Calcium Replacement
PARAPLATIN	carboplatin	J9045	IV	Antineoplastic - Platinum Complexes
KYPROLIS	carfilzomib	J9047	IV	Antineoplastic - Proteasome Enzyme Inhibitors
BICNU	carmustine	J9050	IV	Antineoplastic-Alkylating Agent
ANCEF	cefazolin sodium	J0690	IV	Cephalosporin Antibiotics – 1st Generation
FETROJA	cefiderocol sulfate tosylate	J0699	IV	Cephalosporin Antibiotics - Siderophore
CEFOTAN	cefotetan disodium, 10mg	J0525	IJ	Cephalosporin Antibiotics – 2nd Generation
TEFLARO	ceftaroline fosamil acetate	J0712	IV	Cephalosporin Antibiotics - 5th Generation
MEFOXIN	cefoxitin	J0694	IJ	Cephalosporin Antibiotics – 2nd Generation
LIBTAYO	cemiplimab-rwlc	J9119	IV	Antineoplastic-Anti-Programmed Cell Death Receptor-1 (PD-1) MC Antib.
BRINEURA	cerliponase alfa	J0567	IJ	Drugs to Treat Neuronal Ceroid Lipofuscinosis type 2 (CLN2)

Louisiana MCO Physician Administered (PAD) Drug List

Effective Date: October 1, 2026
(updated 10/2/2026)

Brand Name	Generic Name	HCPCS code	Route	Drug Class
ERBITUX	cetuximab	J9055	IV	Epidermal Growth Factor Recept Blocker (HER-1 Type), Rec-MC Antibody
CARVYKTI	ciltacabtagene autoleucel	Q2056	IV	Antineoplastic - BCMA directed CAR-T cell immunotherapy
CIPROFLOXACIN-D5W	ciprofloxacin lactate/dextrose 5 % in water	J0744	IV	Fluoroquinolone Antibiotics
CLADRIBINE	cladribine	J9065	IV	Antineoplastic - Antimetabolite - Purine Analogs
CLOLAR	clofarabine	J9027	IV	Antineoplastic - Antimetabolite - Purine Analogs
CYTOXAN	cyclophosphamide	J9071	IV	Antineoplastic - Alkylating Agent - Nitrogen Mustards
CYTOXAN	cyclophosphamide	J9072	IV	Antineoplastic - Alkylating Agent - Nitrogen Mustards
CYTOXAN	cyclophosphamide	J9073	IV	Antineoplastic - Alkylating Agent - Nitrogen Mustards
CYTOXAN	cyclophosphamide	J9074	IV	Antineoplastic - Alkylating Agent - Nitrogen Mustards
CYTOXAN	cyclophosphamide	J9075	IV	Antineoplastic - Alkylating Agent - Nitrogen Mustards
CYTOXAN	cyclophosphamide	J9076	IV	Antineoplastic - Alkylating Agent - Nitrogen Mustards
CYCLOSPORINE	cyclosporine	J7516	IV	Immunosuppressive - Calcineurin Inhibitors
CYTARABINE	cytarabine/PF	J9100	IJ	Antineoplastic - Antimetabolite - Pyrimidine Analogs
DACARBAZINE	dacarbazine	J9130	IV	Antineoplastic - Alkylating Agent - Triazenes
COSMEGEN	dactinomycin	J9120	IV	Antineoplastic Antibiotic - Actinomycins
VYXEOS	daunorubicin/cytarabine liposomal	J9153	IV	Antineoplastic - Antibiotic and Antimetabolite Combinations
DECITABINE	decitabine	J0894	IV	Antineoplastic - Antimetabolite - Pyrimidine Analogs
FIRMAGON	degarelix acetate	J9155	SQ	Antineoplastic - LHRH (GnRH) Antagonist Pituitary Suppressants
TOTECT/ZINECARD	dexrazoxane HCl	J1190	IV	Tissue Protective Agents for Tx of Cancer Chemotherapy Extravasation
LACTATED RINGERS	ringers	J7121	IV	Dextrose and Lactated Ringer's Solutions
TAXOTERE	docetaxel	J9171	IV	Antineoplastic - Taxanes

Louisiana MCO Physician Administered (PAD) Drug List

Effective Date: October 1, 2026
(updated 10/2/2026)

Brand Name	Generic Name	HCPCS code	Route	Drug Class
EMPLICITI	elotuzumab	J9176	IV	Antineoplastic - Anti-SLAMF7 Monoclonal Antibody Agents
GAMIFANT	emapalumab-lzsg	J9210	IV	Immunosuppressive - Interferon Inhibitor, Monoclonal Antibody
EPINEPHRINE	epinephrine	J0162	IV	Cardiovascular Sympathomimetics
EPINEPHRINE	epinephrine	J0163	IV	Cardiovascular Sympathomimetics
EPINEPHRINE	epinephrine	J0164	IV	Cardiovascular Sympathomimetics
EPINEPHRINE	epinephrine	J0165	IV	Cardiovascular Sympathomimetics
EPINEPHRINE	epinephrine	J0166	IV	Cardiovascular Sympathomimetics
EPINEPHRINE	epinephrine	J0167	IV	Cardiovascular Sympathomimetics
EPINEPHRINE	epinephrine	J0168	IV	Cardiovascular Sympathomimetics
EPINEPHRINE	epinephrine	J0169	IV	Cardiovascular Sympathomimetics
ELLENCE	epirubicin HCl	J9178	IV	Antineoplastic Antibiotic - Anthracyclines
XERAVA	eravacycline di-hydrochloride	J0122	IV	Tetracycline Antibiotics
HALAVEN	eribulin mesylate	J9179	IV	Antineoplastic - Microtubule Inhibitors
ERYTHROCIN LACTOBIONATE	erythromycin lactobionate	J1364	IV	Macrolide Antibiotics
EXONDYS-51	eteplirsen	J1428	IV	Duchenne Muscular Dystrophy - Exon Skipping Antisense Oligonucleotide
TOPOSAR	etoposide	J9181	IV	Antineoplastic - Epipodophyllotoxins
VABYSMO	faricimab-svoa	J2777	IO	Bispecific VEGF-A and Angiopoietin-2 (Ang-2) Inhibitors
BEQVEZ	fidanacogene elaparvovec-dzkt	J1414	IV	Gene Therapy Agents - Factor IX Deficiency
DIFLUCAN	fluconazole	J1450	IV	Antifungal - Triazoles
PHOSPHATE	fludarabine phosphate	J9185	IV	Antineoplastic - Antimetabolite - Purine Analogs
ADRUCIL	fluorouracil	J9190	IV	Antineoplastic - Antimetabolite - Pyrimidine Analogs

Louisiana MCO Physician Administered (PAD) Drug List

Effective Date: October 1, 2026
(updated 10/2/2026)

Brand Name	Generic Name	HCPCS code	Route	Drug Class
FASLODEX	fulvestrant	J9395	IM	Antineoplastic - Selective Estrogen Receptor Degraders (SERDs)
NAGLAZYME	galsulfase	J1458	IV	Metabolic Disease Enzyme Replacement, Mucopolysaccharidosis
INLEXZO	gemcitabine	J9183	IS	Antineoplastic Agent - Antimetabolite - Pyrimidine Analog
GENTAMICIN SULFATE	gentamicin sulfate	J1580	IJ	Aminoglycoside Antibiotic
VYONDYS-53	golodirsen	J1429	IV	Duchenne Muscular Dystrophy - Exon Skipping Antisense Oligonucleotide
HEPARIN FLUSH	heparin sodium, porcine in 0.9 % sodium chloride	J1642	IV	Heparin Flush Formulations
HEPARIN SODIUM-D5W	heparin sodium, porcine/dextrose 5 % in water	J1643	IV	Heparins
HEPARIN SODIUM	heparin sodium,porcine	J1644	IJ	Heparins
TROGARZO	ibalizumab-uiyk	J1746	IV	Antiretroviral - Anti-CD4 Domain 2 Monoclonal Antibody
IDAMYCIN PFS	idarubicin HCl	J9211	IV	Antineoplastic Antibiotic - Anthracyclines
ELAPRASE	idursulfase	J1743	IV	Mucopolysaccharidosis
IFEX	ifosfamide	J9208	IV	Antineoplastic - Alkylating Agent - Nitrogen Mustards
PRIMAXIN	imipenem/cilastatin sodium	J0743	IV	Carbapenem Antibiotic Combinations
BESPONSA	inotuzumab ozogamicin	J9229	IV	Antineoplastic - Antibody-Drug Conjugates (ADCs)
YERVOY	ipilimumab	J9228	IV	Antineoplastic - Cytotoxic T-Lymphocyte antigen (CTLA-4),R-MC Antibody
CAMPTOSAR	irinotecan HCl	J9206	IV	Antineoplastic - Topoisomerase I Inhibitors
ONIVYDE	irinotecan liposomal	J9205	IV	Antineoplastic - Topoisomerase I Inhibitors
VENOFER	iron sucrose complex	J1756	IV	Minerals and Electrolytes - Iron
SARCLISA	isatuximab-irfc	J9227	IV	Antineoplastic - CD38 Specific Recombinant Monoclonal Antibody Agents

Louisiana MCO Physician Administered (PAD) Drug List

Effective Date: October 1, 2026
(updated 10/2/2026)

Brand Name	Generic Name	HCPCS code	Route	Drug Class
CRESEMBA	isavuconazonium sulfate	J1833	IV	Antifungal - Triazoles
IXEMPRA	ixabepilone	J9207	IV	Antineoplastic - Epothilones and Analogs
LEVAQUIN	levofloxacin	J1956	IV	Fluoroquinolone Antibiotics
KHAPZORY	levoleucovorin	J0642	IV	Methotrexate Rescue Agents
FUSILEV	levoleucovorin calcium	J0641	IV	Methotrexate Rescue Agents
LINCOCIN	lincomycin HCl	J2010	IJ	Lincosamide Antibiotics
ZYVOX	linezolid in dextrose 5 % in water	J2020	IV	Oxazolidinone Antibiotics
BREYANZI	lisocabtagene maraleucel	Q2054	IV	Antineoplastic - CD-19 directed CAR-T cell immunotherapy
ATGAM	lymphocyte immune globulin, antithymocyte (equine)	J7504	IV	Immune Serums
OSMITROL	mannitol, 250 mg	J2151	IV	Diuretic - Osmotic
ALKERAN	melphalan HCl	J9245	IV	Antineoplastic - Alkylating Agent - Nitrogen Mustards
DEMEROL	meperidine HCl/PF	J2175	IJ	Analgesic Opioid Agonists
MESNEX	mesna	J9209	IV	Urinary Tract Protective Agents used in conjunction with Chemotherapy
REGLAN	metoclopramide HCl	J2765	IJ	Gastrointestinal Prokinetic Agents - D2 Antagonist/5-HT4 Agonists
MUTAMYCIN	mitomycin	J9280	IV	Antineoplastic Antibiotic - Others
JELMYTO	mitomycin	J9281	UR	Antineoplastic Antibiotic - Others
MITOXANTRONE HCL	mitoxantrone HCl	J9293	IV	Antineoplastic Antibiotic - Anthracyclines
APHEXDA	motixafortide	J2277	SQ	Antineoplastic - Antimetabolite - Purine Analogs
ADSTILADRIN	nadofaragene firadenovec-vncg	J9029	IS	Antineoplastic - Gene Therapy Agents
DANYELZA	naxitamab-gqgk	J9348	IV	Antineoplastic - Anti-GD2 Ganglioside Monoclonal Antibody

Louisiana MCO Physician Administered (PAD) Drug List

Effective Date: October 1, 2026
(updated 10/2/2026)

Brand Name	Generic Name	HCPCS code	Route	Drug Class
ARRANON	nelarabine	J9261	IV	Antineoplastic - Antimetabolite - Purine Analogs
OPDIVO	nivolumab	J9299	IV	Antineoplastic-Anti-Programmed Cell Death Receptor-1 (PD-1) MC Antib.
SPINRAZA	nusinersen sodium/PF	J2326	IT	Spinal Muscular Atrophy - Exon Inclusion Antisense Oligonucleotide
GAZYVA	obinutuzumab	J9301	IV	Antineoplastic - CD20 Specific Recombinant Monoclonal Antibody Agents
SANDOSTATIN	octreotide acetate	J2353 (Sandostatin LAR Depot)	IJ	Somatostatic Agents
SANDOSTATIN	octreotide acetate	J2354 (Non-depot, fast-acting Sandostatin)	IJ	Somatostatic Agents
NUZYRA	omadacycline tosylate	J0121	IV	Tetracycline Antibiotics
ORBACTIV	oritavancin diphosphate	J2407 (Orbactiv)	IV	Lipoglycopeptide Antibiotics
KIMYRSA	oritavancin diphosphate	J2406 (Kimyrsa)	IV	Lipoglycopeptide Antibiotics
OXACILLIN SODIUM	oxacillin sodium	J2700	IV	Penicillin Antibiotic - Penicillinase-resistant
OXALIPLATIN	oxaliplatin	J9263	IV	Antineoplastic - Platinum Complexes
BOUND	paclitaxel protein-bound	J9264	IV	Antineoplastic - Taxanes
KEPIVANCE	palifermin	J2425	IV	Keratinocyte Growth Factor (KGF)
AREDIA	pamidronate disodium	J2430	IV	Bone Resorption Inhibitors - Bisphosphonates
VECTIBIX	panitumumab	J9303	IV	Epidermal Growth Factor Recept Blocker (HER-1 Type), Rec-MC Antibody
ZEMPLAR	paricalcitol	J2501	IV	Hyperparathyroid Treatment Agents - Vitamin D Analog-Type
SIGNIFOR LAR	pasireotide pamoate	J2502	IM	Somatostatic Agents
ONPATTRO	patisiran sodium, lipid complex	J0222	IV	Amyloidosis Agents-TTR Suppression, RNA Interfering (RNAi) based
ONCASPAR	pegaspargase	J9266	IJ	Antineoplastic - Asparaginase Enzyme Therapy Agents
PEMFEXY	pemetrexed	J9304	IV	Antineoplastic - Antimetabolite - Folic Acid Analogs
NIPENT	pentostatin	J9268	IV	Antineoplastic - Antimetabolite - Purine Analogs

Louisiana MCO Physician Administered (PAD) Drug List

Effective Date: October 1, 2026
(updated 10/2/2026)

Brand Name	Generic Name	HCPCS code	Route	Drug Class
RAPIVAB	peramivir/PF	J2547	IV	Influenza Antiviral Agents - Neuraminidase Inhibitors
PERJETA	pertuzumab	J9306	IV	Epidermal Growth Factor Recept (HER-2) Subdomain II Blocker, Rec-MC Ab
RYPLAZIM	plasminogen, human-tvmh	J2998	IV	Plasma Proteins Which Facilitate Anticoagulation
ZEMDRI	plazomicin sulfate	J0291	IV	Aminoglycoside Antibiotic
MOZOBIL	plerixafor	J2562	SQ	CXCR4 Chemokine Receptor Antagonists
POLIVY	polatuzumab vedotin-piiq	J9309	IV	Antineoplastic - Antibody-Drug Conjugates (ADCs)
FOLOTYN	pralatrexate	J9307	IV	Antineoplastic - Antimetabolite - Folic Acid Analogs
PROTAMINE SULFATE	protamine sulfate	J2720	IV	Reversal Agents - Heparin Antagonists
CYRAMZA	ramucirumab	J9308	IV	Antineoplastic - Vasc Endothelial Growth Factor Receptor (VEGFR) Antag
LUCENTIS	ranibizumab	J2778	IO	Ophthalmic - Macular Degeneration, Age-Related, Therapy Agents
ELITEK	rasburicase	J2783	IV	Hyperuricemia Therapy - Urate-Oxidase Enzyme-Type
LEXISCAN	regadenoson	J2785	IV	Diagnostic Drugs - Cardiovascular
VEKLURY	remdesivir	J0248	IV	SARS-CoV-2 Antiviral Agent - RNA Polymerase Inhibitors
RHOGAM ULTRA-FILTERED PLUS	Rho(D) immune globulin	J2790	IM	Immune Globulin - Rho(D)
TRUXIMA	rituximab-abbs	Q5115	IV	Antineoplastic - CD20 Specific Recombinant Monoclonal Antibody Agents
RIABNI	rituximab-arrx	Q5123	IV	Antineoplastic - CD20 Specific Recombinant Monoclonal Antibody Agents
RUXIENCE	rituximab-pvvr	Q5119	IV	Antineoplastic - CD20 Specific Recombinant Monoclonal Antibody Agents
ISTODAX	romidepsin	J9319	IV	Antineoplastic - Histone deacetylase (HDAC) inhibitors
TRODELVY	sacituzumab govitecan-hziy	J9317	IV	Antineoplastic-TROP2 Directed Antibody-Topoisomerase I Inhib Conjugate

Louisiana MCO Physician Administered (PAD) Drug List

Effective Date: October 1, 2026
(updated 10/2/2026)

Brand Name	Generic Name	HCPCS code	Route	Drug Class
LEUKINE	sargramostim	J2820	IJ	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
PROVENGE	sipuleucel-T/lactated ringers solution	Q2043	IV	Antineoplastic - Immunotherapy, Therapeutic Vaccines
FERRLECIT	sodium ferric gluconate complex in sucrose	J2916	IV	Minerals and Electrolytes - Iron
LANREOTIDE	somatuline	J1930	SQ	Systemic Hormonal Agents-Pituitary and Hypothalmic Hormones
LANREOTIDE	somatuline	J1932 (Cipla)	SQ	Systemic Hormonal Agents-Pituitary and Hypothalmic Hormones
ZANOSAR	streptozocin	J9320	IV	Antineoplastic Antibiotic - Others
MONJUVI	tafasitamab-cxix	J9349	IV	Antineoplastic - CD19 Specific Recombinant Monoclonal Antibody Agents
ELZONRIS	tagraxofusp-erzs	J9269	IV	Antineoplastic-CD123-Directed Cytotoxin (IL-3 and diphth.) Conjugate
ELELYSO	taliglucerase alfa	J3060	IV	Metabolic Disease Enzyme Replacement, Gaucher's Disease
IMLYGIC	talimogene laherparepvec	J9325	IJ	Antineoplastic - Immunotherapy, Virus-Based
VIBATIV	telavancin HCl	J3095	IV	Lipoglycopeptide Antibiotics
TORISEL	temsirolimus	J9330	IV	Antineoplastic - mTOR Kinase Inhibitors
TEPADINA	thiotepa	J9342	IJ	Antineoplastic - Alkylating Agent - Ethylenimines and Methylmelamines
TYGACIL	tigecycline	J3243	IV	Tetracycline Antibiotics
HYCAMTIN	topotecan HCl	J9351	IV	Antineoplastic - Topoisomerase I Inhibitors
TOPOTECAN HCL	topotecan HCl	J9351	IV	Antineoplastic - Topoisomerase I Inhibitors
YONDELIS	trabectedin	J9352	IV	Antineoplastic-Alkylating Agent-Tetrahydroisoquinoline and Derivatives
KANJINTI	trastuzumab-anns	Q5117	IV	Epidermal Growth Factor Recept Blocker (HER-2 Type), Rec-MC Antibody

Louisiana MCO Physician Administered (PAD) Drug List

Effective Date: October 1, 2026
(updated 10/2/2026)

Brand Name	Generic Name	HCPCS code	Route	Drug Class
OGIVRI	trastuzumab-dkst	Q5114	IV	Epidermal Growth Factor Recept Blocker (HER-2 Type), Rec-MC Antibody
ONTRUZANT	trastuzumab-dttb	Q5112	IV	Epidermal Growth Factor Recept Blocker (HER-2 Type), Rec-MC Antibody
HERZUMA	trastuzumab-pkrb	Q5113	IV	Epidermal Growth Factor Recept Blocker (HER-2 Type), Rec-MC Antibody
TRAZIMERA	trastuzumab-qyyp	Q5116	IV	Epidermal Growth Factor Recept Blocker (HER-2 Type), Rec-MC Antibody
HERCESSI	trastuzumab-strf	Q5146	IV	Epidermal Growth Factor Recept Blocker (HER-2 Type), Rec-MC Antibody
COSELA	trilaciclib dihydrochloride	J1448	IV	Bone Marrow Protective Agents used in conjunction with Chemotherapy
TRELSTAR	triptorelin pamoate	J3315	IM	Antineoplastic - LHRH (GnRH) Agonist Analog Pituitary Suppressants
VALSTAR	valrubicin	J9357	IS	Antineoplastic Antibiotic - Anthracyclines
VILTEPSO	viltolarsen	J1427	IV	Oligonucleotide
VELBAN	vinblastine	J9360	IV	Antineoplastic - Vinca Alkaloids and Analogs
VINCASAR PFS	vincristine sulfate	J9370	IV	Antineoplastic - Vinca Alkaloids and Analogs
NAVELBINE	vinorelbine tartrate	J9390	IV	Antineoplastic - Vinca Alkaloids and Analogs
LUXTURNA	voretigene neparvovec-rzyl	J3398	IO	Retinal Pigment Epithelial 65 kDa Protein (RPE65) Gene Therapy
VFEND IV	voriconazole	J3465	IV	Antifungal - Triazoles
RECLAST	zoledronic acid	J3489	IV	Bone Resorption Inhibitors - Bisphosphonates

Louisiana MCO Physician Administered (PAD) Drug List

Revision Log

Revision	Date
Created PAD List Document	6/1/2026
Updated Blenrep HCPCS code from J9037 to J9053	9/28/2026
Removed Protamine Sulfate A4802 - HCPCS code inactive	9/28/2026
Removed Campath J0202, Cubicin RF J0878, Pemetrexed Disodium J9296, Claforan J0698, Cefotan S0074, Chloromycetin Sodium Succinate J0720, Aliqopa J9057, Decitabine J0893, Dacogen J0894, Floxuridine J9200, Zoladex J9202, Osmitrol J2150, Margenza J9353 - Discontinued	9/28/2026
Added Ocrevus Zunovo J2351	10/2/2026